$SKGR
SK Growth Opportunities Corp

2022 Q4 Form 10-K Financial Statement

#000119312523083808 Filed on March 29, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022 2021 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $280.0K $720.0K
YoY Change 2300.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $280.0K $720.0K
YoY Change 2300.0%
Operating Profit -$717.3K -$33.83K
YoY Change
Interest Expense $2.200M $2.830M
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.827M $0.00
YoY Change
Pretax Income $1.920M $2.110M
YoY Change -7133.33%
Income Tax
% Of Pretax Income
Net Earnings $1.920M $2.109M -$33.83K
YoY Change -5775.27% -7131.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.12 $0.13
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $500.0K $500.0K
YoY Change
Cash & Equivalents $515.4K
Short-Term Investments
Other Short-Term Assets $400.0K $400.0K
YoY Change
Inventory
Prepaid Expenses $415.9K
Receivables
Other Receivables
Total Short-Term Assets $931.3K $900.0K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $217.6M $217.6M
YoY Change
Other Assets $200.0K $200.0K
YoY Change
Total Long-Term Assets $217.9M $217.9M $31.99K
YoY Change 681002.29%
TOTAL ASSETS
Total Short-Term Assets $931.3K $900.0K
Total Long-Term Assets $217.9M $217.9M $31.99K
Total Assets $218.8M $218.8M $31.99K
YoY Change 683913.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.331K $0.00
YoY Change
Accrued Expenses $300.5K $300.0K $40.82K
YoY Change 636.18%
Deferred Revenue
YoY Change
Short-Term Debt $5.200M $5.200M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.543M $5.500M $40.82K
YoY Change 13480.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.300M $7.300M
YoY Change
Total Long-Term Liabilities $7.336M $7.300M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.543M $5.500M $40.82K
Total Long-Term Liabilities $7.336M $7.300M
Total Liabilities $12.88M $12.90M $40.82K
YoY Change 31453.34%
SHAREHOLDERS EQUITY
Retained Earnings -$11.64M -$33.83K
YoY Change 34316.1%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$11.64M $205.9M -$8.831K
YoY Change
Total Liabilities & Shareholders Equity $218.8M $218.8M $31.99K
YoY Change 683913.89%

Cashflow Statement

Concept 2022 Q4 2022 2021 Q4
OPERATING ACTIVITIES
Net Income $1.920M $2.109M -$33.83K
YoY Change -5775.27% -7131.16%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$90.00K -$1.214M $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$214.8M
YoY Change
Cash From Investing Activities $0.00 -$214.8M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 216.6M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -90.00K -1.214M 0.000
Cash From Investing Activities 0.000 -214.8M 0.000
Cash From Financing Activities 0.000 216.6M 0.000
Net Change In Cash -90.00K 515.4K 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$90.00K -$1.214M $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001912461
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity Registrant Name
EntityRegistrantName
SK GROWTH OPPORTUNITIES CORPORATION
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022 dei Entity File Number
EntityFileNumber
001-41432
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1643582
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
228 Park Avenue S #96693
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10003
CY2022 dei City Area Code
CityAreaCode
917
CY2022 dei Local Phone Number
LocalPhoneNumber
599-1622
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
213372800
CY2022 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2022 dei Auditor Location
AuditorLocation
New York, New York
CY2022 dei Auditor Firm
AuditorFirmId
100
CY2022Q4 us-gaap Cash
Cash
515410
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
415866
CY2022Q4 us-gaap Assets Current
AssetsCurrent
931276
CY2021Q4 skgr Deferred Offering Costs Non Current
DeferredOfferingCostsNonCurrent
31985
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
204750
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
217645818
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
217850568
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
31985
CY2022Q4 us-gaap Assets
Assets
218781844
CY2021Q4 us-gaap Assets
Assets
31985
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2331
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
300481
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40816
CY2022Q4 skgr Overfunding Loan
OverfundingLoan
5240000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5542812
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40816
CY2022Q4 skgr Deferred Underwriting And Advisory Fees
DeferredUnderwritingAndAdvisoryFees
7336000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7336000
CY2022Q4 us-gaap Liabilities
Liabilities
12878812
CY2021Q4 us-gaap Liabilities
Liabilities
40816
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24425
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11643310
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33831
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11642786
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8831
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218781844
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31985
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
717265
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33831
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-717265
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-33831
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20794
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2805818
CY2021Q4 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2826612
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2109347
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-33831
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
0
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-33831
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-8831
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6792000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
23480261
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2109347
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11642786
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2109347
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-33831
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20794
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2805818
CY2021Q4 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0
CY2022 skgr General And Administrative Expenses Paid By Sponsor In Exchange For Issuance Of Ordinary Shares
GeneralAndAdministrativeExpensesPaidBySponsorInExchangeForIssuanceOfOrdinaryShares
0
CY2021Q4 skgr General And Administrative Expenses Paid By Sponsor In Exchange For Issuance Of Ordinary Shares
GeneralAndAdministrativeExpensesPaidBySponsorInExchangeForIssuanceOfOrdinaryShares
25000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
620616
CY2021Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2331
CY2021Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
121650
CY2021Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8831
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1213900
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0
CY2022 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
214840000
CY2021Q4 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-214840000
CY2021Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
300000
CY2021Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
300000
CY2021Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2022 skgr Proceeds Received From Overfunding Loan
ProceedsReceivedFromOverfundingLoan
5240000
CY2021Q4 skgr Proceeds Received From Overfunding Loan
ProceedsReceivedFromOverfundingLoan
0
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
209600000
CY2021Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6792000
CY2021Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5062690
CY2021Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
216569310
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
515410
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
515410
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
CY2022 skgr Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
170000
CY2021Q4 skgr Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
31985
CY2022 skgr Deferred Underwriting And Advisory Fees As Noncash Investing And Financing Activities
DeferredUnderwritingAndAdvisoryFeesAsNoncashInvestingAndFinancingActivities
7336000
CY2021Q4 skgr Deferred Underwriting And Advisory Fees As Noncash Investing And Financing Activities
DeferredUnderwritingAndAdvisoryFeesAsNoncashInvestingAndFinancingActivities
0
CY2022 skgr Reversal Of Previous Accrued Offering Costs
ReversalOfPreviousAccruedOfferingCosts
31985
CY2021Q4 skgr Reversal Of Previous Accrued Offering Costs
ReversalOfPreviousAccruedOfferingCosts
0
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2021-12-08
CY2022Q2 skgr Total Offering Costs In Connection Within Initial Public Offering
TotalOfferingCostsInConnectionWithinInitialPublicOffering
12000000
CY2022Q2 skgr Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7000000
CY2022Q2 skgr Number Of Days Granted To Underwriters To Subscribe Shares Pursuant To Overallotment Option
NumberOfDaysGrantedToUnderwritersToSubscribeSharesPursuantToOverallotmentOption
P45D
CY2022Q2 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
214800000
CY2022Q2 skgr Per Share Value Of Restricted Asset
PerShareValueOfRestrictedAsset
10.25
CY2022 skgr Businesscombinationconsummateperiodlimit
Businesscombinationconsummateperiodlimit
P185D
CY2022Q4 skgr Percentage Of Public Shares That Can Be Transferred Without Any Restriction
PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction
0.15
CY2022 skgr Percentage Of Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageOfObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2022 skgr Period Within Which Business Combination Shall Be Consummated From The Consummation Of Initial Public Offer
PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheConsummationOfInitialPublicOffer
P18M
CY2022 skgr Period Within Which Business Combination Shall Be Consummated From The Consummation Of Initial Public Offer If A Definitive Agreement Executed Relating To Business Combination
PeriodWithinWhichBusinessCombinationShallBeConsummatedFromTheConsummationOfInitialPublicOfferIfADefinitiveAgreementExecutedRelatingToBusinessCombination
P21M
CY2022Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2022Q4 us-gaap Share Price
SharePrice
10.25
CY2022Q4 us-gaap Share Price
SharePrice
10.25
CY2022Q4 us-gaap Cash
Cash
515000
CY2022Q4 skgr Working Capital
WorkingCapital
4600000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 9pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of December 31, 2022 and 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022 skgr Restricted Investments Term
RestrictedInvestmentsTerm
P185D
CY2021Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022 skgr Deferred Underwriting Commission Per Unit
DeferredUnderwritingCommissionPerUnit
0.35
CY2022 skgr Additional Time Frame For Completion Of Business Combination
AdditionalTimeFrameForCompletionOfBusinessCombination
three months each time for a total of up to 24 months
CY2022 skgr Underwriting Discount Paid Per Unit
UnderwritingDiscountPaidPerUnit
0.2
CY2022 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4000000
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
7000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
990000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
one to one
CY2022Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022 skgr Percentage Of Over Allotment Option Amount Would Be Exercised
PercentageOfOverAllotmentOptionAmountWouldBeExercised
0.25
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-21000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
skgr-20221231_cal.xml Edgar Link unprocessable
0001193125-23-083808-index-headers.html Edgar Link pending
0001193125-23-083808-index.html Edgar Link pending
0001193125-23-083808.txt Edgar Link pending
0001193125-23-083808-xbrl.zip Edgar Link pending
d401334d10k.htm Edgar Link pending
d401334dex311.htm Edgar Link pending
d401334dex312.htm Edgar Link pending
d401334dex321.htm Edgar Link pending
d401334dex322.htm Edgar Link pending
d401334dex45.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g401334g19y12.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
d401334d10k_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skgr-20221231.xsd Edgar Link pending
skgr-20221231_def.xml Edgar Link unprocessable
skgr-20221231_lab.xml Edgar Link unprocessable
skgr-20221231_pre.xml Edgar Link unprocessable